| INTRODUC TI ON
Deregulation of cell cycle control is a hallmark of human cancer. 1 Tumor-associated cell cycle defects are often mediated by alterations in CDK activity, which are regarded as promising targets in cancer therapy. [2] [3] [4] For example, CDK4/6-selective inhibitors, such as palbociclib 
K E Y W O R D S
activin, breast cancer, estrogen receptor, palbociclib, SMAD with cyclin D, phosphorylate the retinoblastoma tumor suppressor protein (RB, encoded by RB1) and its family members, p107 (RBL1, or RB transcriptional corepressor like 1) and p130 (RBL2). When phosphorylated, RB proteins release E2F transcription factors, resulting in the expression of genes required for cell cycle progression from G1 phase into S phase and initiation of DNA synthesis.
Breast cancer is classified into intrinsic subtypes by expression microarray data, 10 Although CDK4/6 inhibitors exert their effects mainly through RB, they still exert a partial cytostatic effect in RB1 knockdown or knockout cells before evolution of compensatory mechanisms. 13, 14 This suggests that CDK4/6 inhibitors exert their effects through other substrates besides RB. Indeed, a systemic screening of 445 human nuclear proteins with at least two CDK consensus sites identified FOXM1, which plays essential roles in CDK4/6-mediated escape from senescence. 15 SMAD2 and SMAD3 are other CDK4 substrates 16, 17 ; they are intracellular signaling components of TGF-β and activin, which convey cytostatic signals in ER-positive breast cancer. 18, 19 SMAD proteins contain highly conserved MH1 and MH2 domains and a less conserved linker region between the two domains. The linker domain is a target for post-translational modification including phosphorylation, which causes either activation of transcription by the SMAD complex or degradation and turnover of SMAD proteins in a context-dependent way. 20 The signaling pathways triggered by TGF-β family members control a wide range of cellular processes. [21] [22] [23] In normal or premalignant cells, TGF-β/activin usually function as tumor suppressors by inhibiting cell proliferation and inducing apoptosis. It is widely accepted that SMAD2/3 activate the cytostatic program through induction of CDK inhibitors (p21 WAF1/CIP1 , p27 KIP1 , and p15
INK4B
) and inhibition of the expression of other cell cycle regulators, such as c-Myc and Cdc25A. 22 However, activation of the SMAD2/3 pathway also induces the expression of transcription factors for EMT, such as SNAIL, SLUG, ZEB1, and ZEB2, which may explain the tumor-promoting effects of TGF-β and activin in aggressive breast cancer. 24 Linker phosphorylation of SMAD may add complexity to the bidirectional roles of TGF-β family members.
Here, we focused on a possible crosstalk between CDK4/6 and TGF-β/activin-SMAD pathways. Consistent with a previous report, 25 several ER-positive breast cancer cell lines were insensitive to TGF-β treatment; we thus used activin A (ActA) for stimulation.
Our data show that CDK4/6 inhibition and the activin-SMAD signaling pathway collectively regulate the cytostatic response. Moreover, CDK4/6 inhibitors may also strengthen the tumor-promoting aspect of SMAD signaling in aggressive breast cancer.
| MATERIAL S AND ME THODS

| Plasmid construction
Human SMAD2 (NM_005901) construct was as previously described. 26 Human CCNG2 (NM_004354.2) was cloned by PCR, sequence-verified, and subcloned into pcDEF3 vectors. 27 Fluorescent, ubiquitination-based cell cycle indicator (Fucci) lentiviral vectors, pCS-EF-mAG-hGeminin(1-110) and pCS-EF-mKO2-hCdt1(30-120), 28 were kindly provided by Dr A. Miyawaki (RIKEN, Wako, Japan). All the constructs for lentivirus production were kindly provided by Dr H. Miyoshi (RIKEN, Wako, Japan; present address, Keio University, Japan).
| Chromatin immunoprecipitation-seq and RNAseq
Chromatin immunoprecipitation-seq and RNA-seq were carried out as described. [29] [30] [31] Raw data are available at NCBI GEO (http://www.
ncbi.nlm.nih.gov/geo/) (GSE117502).
| Statistical analysis
Differences between two experimental groups were analyzed using Welch's t test or analysis of variance (ANOVA) followed by Tukey-Kramer post hoc test for multiple comparison using GraphPad Prism 6 (GraphPad Software, San Diego, CA, USA).
Detailed methods are available in Data S1 and Table S1 .
| RE SULTS
| Palbociclib and activin cooperatively inhibit cell cycle progression
First, we investigated TGF-β/activin signaling activity in two representative ER-positive human breast cancer cell lines, T47D and MCF7. Similar to TGF-β, ActA causes cell cycle arrest through the SMAD pathway, by inducing CDK inhibitors p21 WAF1/CIP1 and/or p27 KIP1 . 19 ActA was able to phosphorylate the C-terminal serine residues of SMAD2 and SMAD3 in both cell lines as reported previously, whereas TGF-β could not phosphorylate the C-terminal serine residues of SMAD2 and SMAD3 in T47D cells ( Figure 1A ). 19, 25 We thus decided to use ActA as a ligand in the present study. ActA mainly phosphorylated SMAD2 in T47D cells, whereas it phosphorylated both SMAD2 and SMAD3 in MCF7, and HaCaT keratinocytes, which were used as a control for SMAD phosphorylation ( Figure 1A ).
A previous study showed that both cells were sensitive to pal- 33 Consistently, both palbociclib and ActA showed cytostatic effects in T47D cells in a BrdU incorporation assay ( Figure 1B ,C); these effects were additive in nature. A similar tendency was obtained in an EdU incorporation assay using flow cytometry ( Figure   S1 ). In addition, we used the Fucci system, 28 To further validate these findings in an unbiased way, we conducted RNA-sequencing (RNA-seq) in T47D cells treated with ActA and palbociclib. We then carried out GSEA using the oncogenic sig-
UP", which contained genes induced after RB1 and RBL1 knockout Figure S2C,G) . These findings suggested a crosstalk between CDK4/6 and activin-SMAD pathways.
In contrast to the cytostatic effects of TGF-β/activin, tumorpromoting effects were not obvious in T47D cells. As for EMT-like changes, ActA was not able to induce the EMT transcription factors in T47D cells ( Figure 1F and Table S2 ). Palbociclib treatment did not affect induction of the EMT transcription factors, and it slightly induced CDH1 (which encodes E-cadherin). Furthermore, expression of mesenchymal marker proteins, N-cadherin (which is encoded by CDH2) and fibronectin (which is encoded by FN1), was extremely low ( Figure 1G ), suggesting that activation of the activin-SMAD pathway is not sufficient to induce the EMT in T47D cells.
| CDK4/6 phosphorylate Ser255 at the SMAD2 linker region
In a previous report, recombinant CDK4 was shown to phosphorylate several Ser/Thr residues of SMAD3, 17 which correspond to Thr8, Thr220, and Ser255 of SMAD2. We carried out screening of the linker phosphorylation sites in T47D cells using anti-phospho-SMAD2 antibodies (Figure 2A ,B). We found that palbociclib strongly decreased phosphorylation of SMAD2 Ser255. Another phosphorylation site, Thr8, was also weakly affected, which is also the target of extracellular signal-regulated kinase (ERK) 36 and CDK2. 37 In T47D Linker phosphorylation of SMAD proteins has been reported to affect the distribution or stability of SMADs. 20 Cell fractionation experiments showed that C-terminally phosphorylated SMAD2 protein was accumulated in the nucleus of the palbociclib-treated T47D cells ( Figure 2E ). Thus, we were not able to detect the difference in ActA- Figure 3B ). We further validated these findings using ChIP-qPCR analysis ( Figure 3C ). Palbociclib treatment significantly increased the enrichment of SMAD2 binding to the PMEPA1
and CDKN2B promoters. These data suggest that palbociclib treatment affects SMAD complex-DNA interaction at the genome level.
We assumed that palbociclib treatment redirected the SMAD com- Figure 3D ).
Furthermore, de novo motif enrichment analyses showed that one of the representative motifs commonly enriched in the SMAD2 binding sites was that for the FOX family genes ( Figure 3E ). FOXA1 has been reported to be a master transcription factor of luminal breast epithelial cells, 38 or a pioneer factor for ER-positive breast cancer cells, 39 suggesting that the SMAD complex binds to the enhancers that are already accessible by FOXA1 in ER-positive cells.
We then validated the SMAD-DNA interaction enhanced by palbociclib. Using a SMAD reporter construct 9 × CAGA-luc, we confirmed that palbociclib treatment enhanced the activin-SMAD signaling pathway ( Figure 4A ). In addition, TGF-β/activin-SMAD target genes, PMEPA1 and CDKN2B, were induced by ActA in T47D cells, and the induction was further enhanced by palbociclib treatment ( Figure 4B ).
This enhancement by palbociclib was at least partially dependent on GSEA analyses showed that the gene set "TGFB_UP.V1_UP" was enriched in the induced genes after palbociclib treatment ( Figure 4D ), which also supports the hypothesis that palbociclib regulates the set of genes through SMAD2. Thus, we concluded that palbociclib treatment enhances SMAD2 binding to the genome and induces the expression of SMAD2 target genes in T47D cells. Cells were treated with 10 μmol/L SB431542 or DMSO for 24 h, and then treated with ActA for 24 h. Data represent mean ± SD of n = 3 independent experiments. D, Gene set enrichment analysis of SMAD2 bound genes. Genes were pre-rank-ordered and analyzed using the oncogenic signatures (C6, MSigDB). Gene sets with a P-value <5% and an FDR q-value <25% were considered significant. Enrichment score is plotted on the y-axis. NES, normalized enrichment score. Cells were treated without (left) or with (right) 50 ng/mL ActA. *P < .05, **P < .01, ***P < .001, ****P < .0001; ANOVA with Tukey-Kramer post hoc test in (A-C)
SMAD2 binding was enhanced after palbociclib treatment, as shown in ChIP-seq data ( Figure 5B) ; this trend was validated in ChIP-qPCR analysis ( Figure 5C ). Moreover, CCNG2 mRNA was induced by ActA and further enhanced by palbociclib treatment ( Figure 5D ). Ectopic expression of cyclin G2 inhibited cell proliferation in T47D cells Figure 3B . C, SMAD2 ChIP-qPCR analysis of T47D cells carried out as in Figure 3C . Data represent mean ± SD of n = 4 independent experiments (*P < .05; Welch's t test). D, qRT-PCR analysis of T47D cells treated with or without ActA and 1 μmol/L palbociclib for 24 h. Data represent mean ± SD of n = 3 independent experiments (***P < .001, ****P < .0001; ANOVA with Tukey-Kramer post hoc test). E, BrdU incorporation assay in T47D cells or T47D cells stably expressing CCNG2. Data were normalized to the control condition. Data represent mean ± SD of n = 3 independent experiments (**P < .01; Welch's t test). F, Kaplan-Meyer analysis of overall survival of breast cancer datasets from Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) 40 ; ER+ subjects, n = 1445. Survival analysis was carried out using a log-rank test. Data of CCNG2 are also presented together with the other genes in Figure S4 (METABRIC). 40 Among the 12 palbociclib-responsive SMAD2 target genes, three genes (CCNG2, CLIC3, H3F3A) could predict good prognosis of ER-positive breast cancer patients ( Figure S4 ). Importantly, CCNG2 was one of them, which was also consistent with a previous report 41 ( Figure 5F ). Importantly, we found that palbociclib and the activin-SMAD signaling pathway regulate cyclin G2 expression in T47D ( Figure 5 ).
|
Cyclin G2, a member of the cyclins family, and homologous to cyclin G1, negatively regulates the cell cycle and contributes to maintaining the quiescent state of differentiated cells, instead of controlling cell cycle progression. 46 Xu et al 47 reported that a TGF-β family member Data represent mean ± SD of n = 3 independent experiments. *P < .05, **P < .01, ****P < .0001; ANOVA with Tukey-Kramer post hoc test in (F-G) target of rapamycin (mTOR) inhibitor rapamycin has been reported to increase CCNG2 mRNA. 41, 50 Interestingly, knockdown of cyclin G2 was reported to dampen the cell cycle-arrest response in fulvestrant-treated MCF7 cells. 41 In addition, cyclin G2 was identified as a target of p63, which functions as a metastatic suppressor in TNBC, 51 suggesting that it serves as a central node for regulation of the cell cycle and/or metastasis of breast cancer cells.
In summary, our data indicate that CDK4/6 inhibition enhances the activin-SMAD signaling pathway and collectively regulates cytostatic effects in T47D, without activating the tumor-promoting functions of the TGF-β/activin-SMAD signaling pathway, such as the EMT program. However, this can happen in aggressive breast cancer cells where the SMAD pathway can enhance motility and invasiveness. Therefore, the indication for CDK4/6 inhibitors needs to be carefully assessed from the aspect of the TGF-β/activin-SMAD signaling pathway. Moreover, addition of an ALK4/5/7 kinase inhibitor to the CDK4/6 inhibitor might be beneficial in patients with highgrade breast cancer, which may have the aggressive aspects of the SMAD signaling pathway.
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